Drugs Made in America Acquisition Ii CORP

Drugs Made In America Acquisition II Corp. has finalized compensation agreements for its CEO and CFO, including deferred cash payments and performance-based equity grants.

Drugs Made In America Acquisition II Corp. has finalized a $1.4 million financing agreement with Tal Alpha Yezum Vekidum Asakim (2003) LTD, including an interim convertible note of $300,000.

Drugs Made In America Acquisition II Corp. secured a $150,000 bridge loan from Alpha Multi Family Office, part of a larger $1.4 million convertible note financing plan to support its business combination efforts.

Drugs Made In America Acquisition II Corp. confirmed its trust account balance remains intact following previously reported improper sponsor withdrawals from its working capital.

Drugs Made In America Acquisition II Corp. announced the resignation of its CEO and Executive Chair following the discovery of significant unauthorized withdrawals and overpayments by its sponsor.

Drugs Made In America Acquisition II Corp. announced the resignation of its CFO, Glenn Worman, and the appointment of Saleem Elmasri as his successor.

Drugs Made in America Acquisition II Corp. reports Q1 2026 results, with net income driven by trust account interest, while continuing search for a business combination.

Drugs Made in America Acquisition II Corp. reports Q3 2025 results, having completed its $500 million IPO and commenced its search for a pharmaceutical business combination target.

Drugs Made In America Acquisition II Corp. (DMIIU) has filed its annual report for the fiscal year ended December 31, 2025, detailing its activities as a blank check company and outlining its strategy for a future business combination.

Director Catherine Do of Drugs Made In America Acquisition II Corp. acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Myron W. Shulgan, a director of Drugs Made In America Acquisition II Corp., acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Drugs Made In America Acquisition II Corp. CFO Glenn Worman acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Lynn Stockwell, CEO of Drugs Made In America Acquisition II Corp., reported significant indirect share acquisitions and transfers to officers, directors, and accredited investors.

Drugs Made In America Acquisition II LLC, a 10% owner, reported significant changes in its beneficial ownership of ordinary shares and derivative securities, including an acquisition of private units and transfers to officers, directors, and accredited investors.

Sridhar G. Prasad, a Director and 10% owner of Drugs Made In America Acquisition II Corp., acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Drugs Made In America Acquisition II Corp., a blank check company, filed an S-1/A for a $500 million initial public offering to target businesses in the pharmaceutical industry.

Drugs Made In America Acquisition II Corp. launches a $500 million initial public offering to target pharmaceutical companies, emphasizing domestic supply chain resilience.

Drugs Made In America Acquisition II Corp., a blank check company, filed an amended S-1 registration statement for a $500 million initial public offering to target the pharmaceutical industry.

Drugs Made In America Acquisition II Corp. files S-1 for a $500 million initial public offering to target pharmaceutical industry businesses.

Drugs Made In America Acquisition II Corp.'s sponsor and CEO, Lynn Stockwell, jointly reported a beneficial ownership of 10.2% of the company's ordinary shares.